A biotech company aiming to prevent and reverse blindness has secured a significant capital injection. Osanni Bio, which develops therapies for retinal diseases, announced it has raised $190.0M in Series B funding.
Osanni Bio distinguishes itself by tackling retinal diseases with an unconventional, design-thinking approach, focusing on areas where others aren't to develop breakthroughs that save eyesight. The company emphasizes its creative and agile innovation in developing therapies to prevent and reverse blindness caused by these multi-factorial conditions.
















